Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Status: RecruitingPhase: Phase 3Diagnosis: Non-Hodgkin's LymphomaNCT ID: NCT01777152
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 13-008
This is a double-blind, randomized, multicenter, phase 3 clinical trial to compare the efficacy and safety of brentuximab vedotin in combination with CHP with the standard-of-care CHOP in patients with CD30-positive mature T-cell lymphomas.
Conducting Institutions: Brigham and Women's Hospital, Dana-Farber Cancer Institute, Beth-Israel Deaconess Medical Center
Overall PI: Eric Jacobsen, MD,
Dana-Farber Cancer Institute
Site-responsible Investigators: Jon Arnason, MD,
Beth Israel Deaconess Medical Center
Contacts: Dana-Farber Cancer Institute:
email@example.comBeth-Israel Deaconess Medical Center:
Cancer Trials Call Center, 617-667-3060